# OnCo record paper-asco-neoadjuvant-therapy-breast-guideline-jco-2021 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-asco-neoadjuvant-therapy-breast-guideline-jco-2021/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-asco-neoadjuvant-therapy-breast-guideline-jco-2021" ;
  schema:name "Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline"@en ;
  schema:description "The US oncology society's 2021 rules for treatment before surgery: triple-negative tumours of 1 cm or more, or with involved nodes, should get anthracycline and taxane chemotherapy, carboplatin may be added, and at that date the evidence for adding immunotherapy was judged insufficient."@en ;
  schema:url <https://onco.cc/key-papers/paper-asco-neoadjuvant-therapy-breast-guideline-jco-2021/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.20.03399>, <https://pubmed.ncbi.nlm.nih.gov/33507815/>, <https://ascopubs.org/topics/asco-guidelines/breast-cancer> ;
  onco:tag "tnbc-evidence" ;
  schema:sameAs <https://doi.org/10.1200/JCO.20.03399> ;
  schema:datePublished "2021"^^xsd:gYear ;
  schema:author "Korde LA, Somerfield MR, Carey LA, et al." ;
  onco:related <https://onco.cc/key-papers/paper-asco-pembrolizumab-early-tnbc-rapid-update-jco-2022/>, <https://onco.cc/key-papers/paper-shelley-hwang-j-clin-oncol-2021/> ;
  onco:cancers <https://onco.cc/cancers/tnbc/> ;
  onco:drugs <https://onco.cc/drugs/carboplatin/> ;
  onco:institutions <https://onco.cc/institutions/asco/> ;
  onco:terms <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/terms/pcr/>, <https://onco.cc/terms/anthracycline/>, <https://onco.cc/terms/taxane/> ;
  onco:journals <https://onco.cc/journals/jco/> .